Natural killer (NK) cells are cytotoxic lymphocytes that substantially contribute to the therapeutic benefit of antitumor antibodies like Rituximab, a crucial component in the treatment of B-cell malignancies. In chronic lymphocytic leukemia (CLL), the ability of NK cells to lyse the malignant cells and to mediate antibody-dependent cellular cytotoxicity upon Fc receptor stimulation is compromised, but the underlying mechanisms are largely unclear. We report here that NK-cells activation-dependently produce the tumor necrosis factor family member 'B-cell activating factor' (BAFF) in soluble form with no detectable surface expression, also in response to Fc receptor triggering by therapeutic CD20-antibodies. BAFF in turn enhanced the metabolic activity of primary CLL cells and impaired direct and Rituximab-induced lysis of CLL cells without affecting NK reactivity per se. The neutralizing BAFF antibody Belimumab, which is approved for treatment of systemic lupus erythematosus, prevented the effects of BAFF on the metabolism of CLL cells and restored their susceptibility to direct and Rituximab-induced NK-cell killing in allogeneic and autologous experimental systems. Our findings unravel the involvement of BAFF in the resistance of CLL cells to NK-cell antitumor immunity and Rituximab treatment and point to a benefit of combinatory approaches employing BAFF-neutralizing drugs in B-cell malignancies.
INTRODUCTION
Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that play an important role in the immunosurveillance of hematological malignancies. Their reactivity is governed by the integration of activating and inhibitory signals propagated by a multitude of surface receptors that determine the quality and intensity of NK-cell responses. 1 Owing to their ability to mediate antibody-dependent cellular cytotoxicity (ADCC) upon triggering of the Fcγ Receptor IIIa (CD16), they substantially contribute to the therapeutic success of antitumor antibodies like Rituximab. 2 The latter has become an essential component of most treatment strategies for B-cell malignancies. 3, 4 Over the recent years, several studies reported that the ability of NK cells to directly lyse the malignant cells and to mediate ADCC is compromised in chronic lymphocytic leukemia (CLL). [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The molecular mechanisms underlying these observations, however, remain largely unclear.
In this study, we demonstrate that the resistance of CLL cells to direct and Rituximab-induced NK-cell reactivity is facilitated by the tumor necrosis factor (TNF) family member 'B-cell activating factor' (BAFF). BAFF and its close homologue 'A proliferation inducing ligand' (APRIL) are mainly produced by immune cells of the myeloid lineage and bind to the two receptors 'B-cell maturation antigen' (BCMA) and 'transmembrane activator and cyclophilin ligand interactor' (TACI), while BAFF additionally binds to BAFF receptor (BAFFR). Both are critical factors for proliferation, function and survival of peripheral B cells. While at least partially discrepant findings have been reported for APRIL, BAFF plays a prominent pathophysiological role in autoimmune diseases (for reviews see Mackay and Schneider as well as Dillon et al. 16, 17 ). Accordingly, a BAFF-neutralizing antibody termed Belimumab (Benlysta) and a BAFF-and APRIL-inhibiting soluble TACI-Ig molecule (Atacicept) have been developed, the first being approved for treatment of systemic lupus erythematosus and the latter being evaluated in advanced phase clinical trials. 18, 19 Both BAFF and APRIL also contribute to the pathophysiology of B-cell malignancies by acting as anti-apoptotic and pro-survival factors. [20] [21] [22] [23] [24] [25] We demonstrate that NK cells produce BAFF, in particular upon activation, and this includes triggering of their Fc receptor by immunostimulatory CD20 antibodies used in CLL treatment. We further show that NK-cell-derived BAFF enhances the metabolic activity of CLL cells and notably also diminishes their susceptibility to direct NK-cell lysis and Rituximab-induced ADCC. Finally, we report that the CLL-protective effects of BAFF can be neutralized by treatment with Belimumab, which sensitizes the leukemia cells to lysis. Our findings not only identify a biological mechanism underling the pronounced resistance of lymphoid malignant cells to direct and Rituximab-induced NK-cell antitumor immunity, they also unravel the potential of BAFF-blocking agents to reinforce NK-cell reactivity for immunotherapy of B-cell malignancies.
MATERIALS AND METHODS Cells
Peripheral blood mononuclear cells (PBMCs) from CLL patients were obtained at time of diagnosis prior to therapy. All patients declared written informed consent in accordance with the Helsinki protocol, and the study was performed according to the guidelines of the local ethics committee. Polyclonal NK cells (pNKCs) were generated using K562-41BBL-IL15 feeder cells obtained from St Jude´s Children´s Research Hospital as previously described. 26 Resting NK cells and monocytes were purified by MACS isolation (Miltenyi, Bergisch-Gladbach, Germany). Purity of cell preparations was confirmed by fluorescence-activated cell sorting (FACS) and always above 90%. 293-BAFF transfectants and parental controls were described previously. 27 Antibodies and recombinant BAFF Recombinant human BAFF (rhBAFF) was from Immunotools (Friesoythe, Germany). BAFF mAb 1D6 was from eBioscience (San Diego, CA, USA). The anti-mouse PE-conjugate was from Dako (Glostrup, Denmark). Rituximab and Obinutuzumab were from Roche (Basel, Switzerland), Ofatumumab and Belimumab were from GlaxoSmithKline (Brentford, UK). All other antibodies were from BD Pharmingen (San Diego, CA, USA).
PCR analysis
RT-PCR was performed as described previously. 28 Primers were 5′-CCTCAC GGTGGTGTCTTTCT-3′ and 5′-AAAGCTGAGAAGCCATGGAA-3′ for BAFF and 5′-GAGTCAACGGATTTGGTCGT-3′ and 5′-TTGATTTTGGAGGGATCTCG-3′ for GAPDH.
Flow cytometry
NK cells were incubated with BAFF mAb or isotype control mAb (10 μg/ml each) followed by the secondary phycoerythrin conjugate (1:100). Intracellular staining was performed using the Cytofix/Cytoperm from BD Biosciences (San Jose, CA, USA) with phycoerythrin-conjugated 1D6 mAb or isotype control according to the manufacturer´s instructions. NK cells and CLL cells were selected by counterstaining for CD56 + /CD3and CD5 + / CD19 + , respectively. Analysis was performed using a FC500 (Beckmann Coulter, Krefeld, Germany). Specific fluorescence indices were calculated by dividing median fluorescence obtained with specific mAb by median fluorescence obtained with control. Positivity was defined as specific fluorescence index ⩾ 1.5.
FACS-based analysis of CLL cell lysis
Rituximab-induced lysis of CLL cells by autologous NK cells was determined by FACS as previously described. 29 In brief, PBMCs of CLL patients were cultivated in the presence or absence of 500 ng/ml BAFF, Belimumab or control antibody (10 μg/ml each) for 48 h. Then, Rituximab (10 μg/ml) was added where indicated for additional 24 h. Afterwards dying and dead CD19 + /CD5 + CLL cells were identified by FACS owing to 7aminoactinomycin D positivity. Analysis of equal assay volume was ascertained by adding standard calibration beads. Percentage of living cells was calculated from triplicate measurements as follows: 7aminoactinomycin D negative cells upon treatment/7-aminoactinomycin D negative cells in control × 100.
Enzyme-linked immunosorbent assay BAFF levels in supernatants were determined by ELISA according to the manufacturer's instructions using the matched-pair detection set from Adipogen (Liestal, Switzerland). Results are shown as means of triplicate measurements with s.e.m.
Metabolic activity
Primary CLL cells were plated at 2 × 10 6 per well and metabolic activity was measured after 72 h using the Cell Proliferation Reagent WST-1 set from Roche according to the manufacturer's instructions. Results are shown as means of triplicate measurements with s.e.m.
NK-cell activation, degranulation and cytotoxicity
Upregulation of CD69 and CD107a as markers for NK-cell activation and degranulation, respectively, was analyzed by FACS. Direct cytotoxicity and ADCC of NK cells against CLL cells were analyzed by 2 h BATDA Europium assays as described previously. 30 Purification of NK-cell-derived BAFF Belimumab and Rituximab as control were immobilized on CNBr-activated Sepharose 4B (GE Healthcare, Chalfont St Giles, UK) according to the manufacturer's recommendations. Concentrated NK-cell supernatant was then recirculated on a serial two-column setup overnight at 4°C followed by elution with sodium citrate pH 2.5. Eluates were neutralized, concentrated and washed with phosphate-buffered saline by ultrafiltration. Eluates of the Belimumab column underwent a second round of purification under identical conditions.
Peptide mass-fingerprint analysis
Eluates from Belimumab-coated columns were pretreated with dithiothreitol and iodacetamide followed by digestion with Trypsin (Sigma Aldrich, St Louis, MO, USA). After ZipTipC18 (Millipore, Schwalbach, Germany) purification and desalting, peptides were analyzed by liquid chromatography-mass spectrometry/mass spectrometry (UltiMate 3000 RSLCnano UHPLC system and LTQ orbitrap XL, Thermo Fisher, Waltham, MA, USA) followed by data processing and peptide annotation against the human proteome as comprised in the Swiss-Prot database (www.uniprot. org), as described previously. 31 Search was restricted by enzymatic tryptic specificity. Possible methionine oxidation and carbamidomethyl modifications of cysteines were taken into account. The false discovery rate was limited to a high confidence to qo 0.01 (1% false discovery rate).
RESULTS

BAFF is activation-dependently produced by NK cells as soluble, but not as surface-expressed protein
A previous study reported that activated NK cells express BAFF at the protein level, 32 but whether it is expressed on the cell surface or released in soluble form was not studied. After characterizing available reagents for BAFF detection (Supplementary Figure 1A) , we performed FACS analyses with resting NK cells within PBMCs of healthy donors as well as pNKCs. We found that NK cells express no or very low levels of surface BAFF (Figure 1a and Supplementary Figure 1B) . NK cells were also surface-negative for APRIL, which reportedly is not produced in a membrane-bound form. 33 Notably, mRNA of both BAFF and APRIL was detected by RT-PCR in resting and polyclonal NK cells ( Figure 1b and data not shown). Next, we analyzed culture supernatants from isolated resting NK cells and pNKCs for BAFF and APRIL by ELISA. APRIL was never detectable, whereas soluble BAFF was produced by NK cells in all cases with higher levels observed with pNKCs ( Figure 1c and data not shown). In line, BAFF protein was detected by intracellular FACS analysis in NK cells among PBMCs of healthy donors, pNKCs and notably also in NK cells of CLL patients, which displayed pronounced BAFF levels ( Figure 1d ).
To determine whether and how BAFF production by NK cells is regulated, pNKCs were cultured alone or in the presence of the cytokines IL-2 and IL-15 which induce a potent general activation. To mimic CD16 stimulation, we employed culture of the NK cells on immobilized Rituximab, Ofatumumab and Obinutuzumab, the three CD20 antibodies approved for CLL treatment. Although induction of BAFF surface expression was never observed, all stimuli significantly increased the release of soluble BAFF, which was mirrored by enhanced BAFF mRNA levels in NK cells. Ofatumumab and Obinutuzumab, which mediate more pronounced immunostimulatory effects as compared with Rituximab, 34 
BAFF stimulates metabolic activity and protects CLL cells from direct and Rituximab-induced NK lysis
Next, we employed primary CLL cells in WST-1 assays, which revealed a dose-dependent induction of leukemia cell metabolic activity upon exposure to rhBAFF (Figure 2a ). Then, we purified BAFF from NK-cell culture supernatants and analyzed this preparation (nkBAFF) by liquid chromatography-mass spectrometry/mass spectrometry. Tryptic peptides in preparations of 293-BAFF transfectants as control covered most of the sequence of soluble BAFF, and some of these fragments were also identified upon analysis of nkBAFF (Tables 1A and B ). 36 It is noteworthy that one of these peptides has a distinct sequence in cows, excluding the possibility that it could originate from fetal calf serum used in these cultures. WST-1 assays with primary CLL cells revealed that the nkBAFF purified using a Belimumab-coated column clearly stimulated the metabolic activity of the leukemia cells ( Figure 2b) nkBAFF (Figure 2c and d) . Finally, to more closely mirror the situation in patients, functional analyses were performed with freshly isolated PBMCs of CLL patients. FACS-based determination of CLL cell viability after incubation in the presence or absence of BAFF and/or Rituximab confirmed that rhBAFF significantly (P o 0.05, Student's t-test) and sometimes fully protected the malignant B cells from Rituximab-induced lysis by the patient's own NK cells (Figure 2e ). This protective effect was also observed with nkBAFF ( Figure 2f ).
BAFF reduces CLL cell susceptibility to lysis without affecting NK-cell reactivity Next, we incubated CLL cells with or without BAFF for 24 h followed by washing of the leukemic cells to exclude an influence of soluble NK-inhibitory factors potentially induced in CLL cells by BAFF exposure. Afterwards, pNKCs were cocultured with the CLL cells in the absence of BAFF, which further excluded direct effects of BAFF on the effector cells. Neither in the presence nor absence of Rituximab relevant effects of BAFF pretreatment on NK-cell degranulation and activation as revealed by FACS for CD107a and CD69, respectively, were observed. Notably, this held true with allogenic NK cells and also in our autologous experimental setting employing PBMCs of CLL patients directly obtained ex vivo (Figure 3 ). In line, BAFF exposure of the leukemic cells did not alter the expression of immunoregulatory molecules that reportedly influence NK-cell reactivity against CLL cells (for example, classical and non-classical HLA class I molecules, NKG2D ligands, etc.) or CD20-expression (data not shown). We further observed that BAFF did not affect CLL cell proliferation (at least in our in vitro setting), but significantly (all P o 0.05, Student's t-test) protected the leukemic cells from spontaneous apoptosis and sustained their survival. Although no effect on the expression of death receptors (TRAILR, TNFR1 and CD95/Fas) was detected, this protective effect of BAFF for CLL cells was mirrored by a reduction of cleaved PARP as component of their apoptosis machinery ( Supplementary  Figure 2 and data not shown). These results provide evidence that BAFF protects CLL cells from lysis without affecting NK reactivity per se.
BAFF neutralization by Belimumab restores CLL cell susceptibility to direct and Rituximab-induced NK lysis
Finally, we determined whether neutralization of BAFF by Belimumab could serve to therapeutically overcome its protective effects on CLL cells. First, primary CLL cells were exposed to rhBAFF in the presence or absence of Belimumab or control mAb for 72 h. Subsequent WST-1 assays revealed that the presence of Belimumab prevented the BAFF-mediated increase of CLL cell metabolic activity (Figure 4a ). Second, we studied whether Belimumab also prevented the BAFF-induced resistance of CLL cells to NK-cell attack. Cytotoxicity assays revealed that the addition of Belimumab abrogated the protective effect of BAFF for CLL cells and significantly (all P o0.05, Student's t-test) restored both direct and Rituximab-induced lysis by allogeneic NK cells (Figure 4b) . Similar results were obtained in our autologous experimental system when NK reactivity was induced by treatment with Rituximab for 24 h: FACS-based lysis assays revealed that Belimumab significantly (all P o0.05, Student's t-test) prevented the BAFF-mediated resistance of CLL cells to ADCC (Figure 4c ). Overall, these results demonstrate that Belimumab treatment may serve to overcome the protective effects of BAFF and to reinforce direct and Rituximab-induced NK lysis in CLL.
DISCUSSION
Owing to their ability to mediate natural and antibody-induced lysis of target cells, NK cells play an important role in antitumor immunity. 1, 2 Induction of NK-cell ADCC contributes to the therapeutic effects of antitumor antibodies. It is meanwhile firmly established that this important antibody function largely contributes to the success of Rituximab, which is routinely used for the treatment of B-cell malignancies including CLL. 3, 4 However, multiple reports over the last three decades described that in CLL, the ability of NK cells to target the malignant cells is compromised. Both, low susceptibility of the leukemic cells to NK attack and impaired reactivity of patient NK cells have been reported, and notably, this was observed with regard to direct and antibodyinduced cytotoxicity. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The reportedly higher expression of NKinhibitory HLA class I as well as lower levels of ligands for activating receptors like CD155 and CD112 in lymphoid as compared with myeloid leukemias contribute to the same. 10 With regard to CLL in particular, not only the downregulation of activating receptors like NKG2D and NKp30 on patient NK cells, but also release of the NKp30 ligand BAG6 in soluble form as well as pronounced expression of NK-inhibitory molecules like nonclassical HLA and various TNF family members by the malignant cells play a role. 9, 13, 29, [37] [38] [39] Here, we identified the TNF family member BAFF as a mediator of CLL cell resistance to NK-cell attack: exposure of CLL cells to BAFF profoundly reduced direct and Rituximab-induced NK lysis as revealed by analyses with primary leukemic cells and allogeneic 'healthy' as well as autologous patient NK cells. With regard to this CLL-protective effect, our finding that NK cells themselves produce BAFF is of particular interest. In general, BAFF is mainly expressed and released in soluble form by myeloid cells like monocytes/macrophages, dendritic cells and neutrophils. However, cells of the lymphoid lineage like B and T cells have also been reported to express BAFF, in particular upon activation. 16 Here, we report that NK cells as innate components of the lymphoid lineage produce BAFF as a soluble factor dependent on their activation state, whereas relevant surface expression was never detected. In most cell types, BAFF is expressed on the surface and cleaved by a furin convertase. 27 In NK cells, BAFF could be processed intracellularly and released without being expressed in a membrane-bound form, as reported for neutrophils. 40 We also detected BAFF protein intracellularly in NK cells of healthy donors and notably also of CLL patients. Both intracellular BAFF levels and release of soluble protein were increased upon general NK-cell activation with the cytokines IL-2 and IL-15, which is in line with a previous study that reported on BAFF expression by NK cells at the protein level by western blot. 32 Notably, enhanced BAFF production was also detected upon CD16 stimulation with Rituximab, and even more pronounced effects were observed with Ofatumumab and Obinutuzumab, the novel CD20 antibodies approved for CLL therapy. In particular, Obinutuzumab, which is glycoengineered to enhance its affinity to CD16, 34, 35 mediated significantly stronger BAFF induction as compared with Rituximab.
Liquid chromatography-mass spectrometry/mass spectrometry confirmed that BAFF was released by NK cells and was present in the nkBAFF preparations employed in functional assays. Alike rhBAFF, nkBAFF mediated profound resistance of CLL cells to direct and Rituximab-induced NK lysis in allogeneic and autologous experimental assay systems. Notably, the activation and degranulation of allogeneic and autologous NK cells both in the absence and presence of Rituximab were not affected by BAFF pretreatment of CLL cells. It is therefore unlikely that the reduction of NK lysis was due to decreased immunogenicity of the leukemic cells. In line, we did not observe effects of BAFF on the expression of various surface molecules that reportedly influence NK reactivity against CLL cells or CD20, the target for the therapeutic antibodies employed in CLL treatment. Rather, BAFF protects from NK-cell-induced cell death, which is supported by our observation that both rhBAFF and nkBAFF stimulated metabolic activity, decreased apoptosis and sustained survival of CLL cells. The latter is in line with findings of other investigators, which reported that BAFF protects CLL cells from apoptosis and enhances NF-κB activity. 22, 23 The exact molecular mechanism of how BAFF protects CLL cells from NK lysis, however, was not addressed in our study and remains to be elucidated.
Certainly, NK cells are not the only source of BAFF for CLL cells. Besides components of the microenvironment, the malignant cells themselves can express BAFF. 20, 22, 23 Nevertheless, nkBAFF may contribute to the reportedly compromised efficacy of NK cells to target CLL cells, as NK-cell activation upon encounter of the malignant cells would result in locally enhanced BAFF levels. Particularly upon antibody treatment, induction of BAFF release by NK cells and the resulting resistance to lysis may be counterproductive for the eradication of the leukemia cells and limit therapeutic efficacy in CLL.
On the basis of these considerations, our finding that Belimumab, which is approved for systemic lupus erythematosus treatment, abrogates the CLL-protective effects of BAFF is of particular interest. Besides increasing the immunostimulatory capacity of an antibody itself, it is rational to enhance its therapeutic efficacy by preventing mechanisms that allow for tumor immune evasion. For CLL, our approach to reinforce antitumor immunity by BAFF neutralization with Belimumab (but likely also other BAFF-blocking reagents) appears very promising. The benefit of BAFF neutralization reported in our study was, like the role of BAFF in NK-cell immunosubversion per se, proven by using primary leukemia cells of CLL patients with allogenic and autologous human NK cells as effectors. The advantage of this experimental model is that it not only precludes artifacts caused by differences of expression and/or function of BAFF or other TNF superfamily members, but also Fc receptor expression/function and the mechanisms and cell types that mediate ADCC in mice and men. 30, [41] [42] [43] [44] [45] [46] Taken together, the data presented in this study not only provide the first evidence for the involvement of (NK-cell-derived) BAFF in the impaired susceptibility of CLL cells to direct and Rituximab-induced NK-cell reactivity, they also suggest that combining Belimumab with Rituximab, but likely also with Obinutuzumab, Ofatumumab and other systemic treatment modalities will be beneficial for CLL therapy. Supporting evidence for this notion is derived from a clinical case, where Belimumab sensitized a patient with autoimmune disease for Rituximab treatment. 47 Future combinatorial clinical studies based on the findings presented in this report will be required to validate in vivo our conclusion that Belimumab enhances NK-cell reactivity and ADCC in CLL.
